VCL 6365
Alternative Names: CMV prophylactic DNA vaccine - Vical; CyMVectin; Cytomegalovirus DNA vaccine monovalent - Vical; Cytomegalovirus prophylactic vaccine - Vical; gB CMV vaccine - Vical; Vaxfectin; Vaxfectin formulated cytomegalovirus prophylactic DNA vaccine - VicalLatest Information Update: 16 Mar 2018
At a glance
- Originator Vical
- Class Cytomegalovirus vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 16 Mar 2018 Discontinued - Preclinical for Cytomegalovirus infections (Prevention) in USA (IM)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in USA (IM, Injection)
- 18 May 2016 Vical and the Virginia Commonwealth University withdraw a phase I study for Cytomegalovirus infections (Prevention) in USA prior to enrolment (NCT02594566)